Partnerships
We work with pharma collaborators in three ways. Each one has a different purpose, a different timeline, and a different ownership shape. If you are considering a partnership, this page describes each model.
Models
A short, focused collaboration that answers a single question: does a target we have identified matter in human disease. We bring the assay and the molecules; the partner brings the disease biology.
A shared program from candidate nomination through proof-of-concept. We bring the molecule and early clinical work; the partner brings later-stage development and commercial reach.
A multi-target license to use our structure-guided discovery platform against a defined target list. The partner runs discovery in their labs; we provide the platform and the know-how.
Process
30 minutes with our head of business development to align on scope.
A technical conversation with two scientists from each side, plus a written summary.
A short, written term sheet within two weeks of diligence.
Legal drafting in parallel with planning; signed agreement within 60 days of term sheet.
six active programs, two research sites, one contact route. Expect a reply within five business days.